论文部分内容阅读
目的:探讨糖尿病(diabetes,DM)患者发生急性ST段抬高心肌梗死(STEMI)后,在急诊经皮冠状动脉介入治疗(PCI)前应用国产替罗非班的有效性和安全性。方法:入选连续收治的86例有DM的STEMI患者,随机分为术前应用替罗非班组,41例,对照组(未应用替罗非班),45例,比较两组用药后30天及术后6个月心血管事件及出血并发症。结果:术后两组患者与穿刺有关并发症均为9例,术后1个月替罗非班组心血管事件6例,对照组15例(P=0.044),术后6个月罗非班组心血管事件9例,对照组19例(P=0.045),术后替罗非班组肌钙蛋白恢复时间(5.5±2.1)天,对照组(7.9±2.9)天(P=0.046)。结论:急诊PCI前应用国产替罗非班治疗有DM的STEMI患者安全有效,能减少术后1及6个月内心血管事件的发生。
Objective: To investigate the efficacy and safety of domestic tirofiban before emergency percutaneous coronary intervention (PCI) after acute ST-segment elevation myocardial infarction (STEMI) in patients with diabetes mellitus (DM). Methods: Totally 86 STEMI patients with DM were enrolled in the study. They were randomly divided into pretreatment with tirofiban, 41 cases, control group (no tirofiban), 45 cases, 30 days after treatment and Six months after surgery, cardiovascular events and bleeding complications. Results: There were 9 complications related to puncture in both groups. One month after operation, 6 cases of cardiovascular events and 15 cases of control group (P = 0.044) 9 cases of cardiovascular events and 19 cases of control group (P = 0.045). Troponin recovery time was (5.5 ± 2.1) days in control group and 7.9 ± 2.9 days in control group (P = 0.046) after operation. Conclusion: It is safe and effective to treat STEMI patients with DM treated with Tirofiban before emergency PCI, which can reduce the occurrence of cardiovascular events within 1 and 6 months after operation.